Multibagger Selection: Grok 4's picks
Grok 4 picked INOD, PVLA, NRIX, KOD, AEVA with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Grok 4 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | INOD | — | 72% | — | — |
| 2 | PVLA | — | 68% | — | — |
| 3 | NRIX | — | 65% | — | — |
| 4 | KOD | — | 60% | — | — |
| 5 | AEVA | — | 55% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +35.16% | +35.19% | 3.15x | 1 |
| 1 month | +21.45% | +22.24% | 3.30x | 1 |
The model's market view
Small- and mid-cap equities face mixed conditions with selective rotation into growth and catalyst-driven names amid elevated rates and AI infrastructure spending. Liquidity remains adequate for liquid names above $5M daily dollar volume, but biotech binary events and execution-sensitive technology ramps dominate asymmetric upside opportunities within the $200M-$5B market-cap band.
Why each pick
INOD
Innodata is delivering sustained high-teens to mid-40s percent revenue growth driven by AI training data, model evaluation, and enterprise AI platforms, with expanding gross margins, positive and growing free cash flow, and institutional accumulation. Valuation leaves room for multiple expansion if growth persists above 30 percent and margins continue to scale.
PVLA
Palvella has completed rolling NDA submission for QTORIN rapamycin in microcystic lymphatic malformations after positive Phase 3 data, with potential first-in-disease approval and commercial launch targeted for H1 2027. Strong cash position and multi-indication platform create asymmetric upside if regulatory path remains clear.
NRIX
Nurix secured a transformative Roche collaboration for bexobrutideg with $700M upfront and up to $2.3B total potential value, plus 50/50 U.S. profit share, materially de-risking development and providing substantial non-dilutive capital while advancing registrational programs in CLL and other indications.
KOD
Kodiak has completed enrollment in the pivotal Phase 3 DAYBREAK study of Zenkuda and KSI-501 in wet AMD, with topline data expected in the second half of 2026. Positive results would de-risk a BLA-ready profile across multiple retinal indications and support substantial re-rating from the current clinical-stage valuation.
AEVA
Aeva is progressing multiple production-intent automotive programs (Daimler Truck targeted 2027 SOP) and has launched an Optical Connectivity business with a joint development agreement targeting hyperscaler deployments starting H2 2027. Revenue remains early but capacity expansion and design wins create potential for material acceleration.
Other models on the same run
| Model | Picks |
|---|---|
| Claude Opus 5 | ICHR, RUM, OUST, USAR, EMAT |
| Muse Spark 1.1 | KPLT, INDP, BNC, CHPT, SWVL |
| Gemini 1.5 Pro | RCAT, LUNR, POET, SMR, ENVX |
| DeepSeek | RCAT, RZLV, BBAI, UPST, RH |
| GPT-6 | AMPX, OSS, BKSY, INDI, RDW |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.